HRL — Hormel Foods Corporation

The market's immediate reaction to Q3 was clearly negative: the stock fell from $23.71 to $21.275, and the technical picture is deeply oversold. The revenue miss, guided-down organic sales expectations, continued consumer weakness, and a non-cash impairment in International weighed more than the adjusted EPS beat and margin expansion. Wall Street is mostly at Hold, with a split of 6 buy / 17 hold / 7 sell, and the consensus target around $24.33–$26.00 is now only modestly above the current price.

Revenue has been roughly flat-to-stagnant for three years: TTM sales are about $12.15B versus $12.06B a year earlier. YoY revenue growth over the last four quarters was +1.5%, +1.3%, +2.5%, and -2.4%, with the latest quarter hurt by portfolio-shaping exits and lower commodity prices. GAAP earnings are noisy — Q4 FY25 had a -$56M net loss and Q3 FY26 GAAP net income was only $60M due to impairments and one-time items — but the underlying adjusted picture improved: Q3 adjusted EPS of $0.37 beat consensus, adjusted operating margin expanded 60bps to 9.0%, and FY26 adjusted EPS guidance was raised to $1.45–$1.51. This is an inflection on margins, not on top-line growth.

On trailing GAAP earnings, HRL looks expensive at 33.8x, but that is because TTM GAAP EPS of $0.62 is depressed by one-time charges and impairment losses. On forward adjusted earnings, it is much cheaper: using FY26 guidance midpoint of $1.48, the forward P/E is about 14.4x, and using next-FY consensus EPS of $1.50 it is about 14.2x. That is well below HRL's 5-year average P/E of 24.25x. Price-to-sales of 0.96x also sits well under the 5-year average of 1.6x, and price-to-book is 1.09x. Net assessment: fair to moderately cheap on normalized/forward earnings, but not a bargain if revenue keeps shrinking.

As of 2026-08-27, the market is pricing in continued top-line deterioration and largely ignoring the raised EPS guidance and margin recovery. At $21.275, the stock implies roughly 14.4x forward adjusted EPS — a defensive-staples multiple that already bakes in low growth. The play here is not momentum; it's mean-reversion on margins plus the 4.8% dividend yield. If adjusted EPS lands at $1.48–$1.51 and revenue merely stabilizes, the stock should trade above $21. If sales keep sliding or management cuts guidance, the cheap multiple is justified and the stock could test the $19.70 low.

As of 2026-08-27, RSI(14) was 21.5, firmly in oversold territory. The stock was 12.6% below its 20-day SMA, 14.2% below its 50-day SMA, and 9.3% below its 200-day SMA — every trend measure is down. The 10.3% one-day drop to $21.275 puts HRL just above the 52-week low of $19.70. This is a falling knife from a trend standpoint; buying early could work for long-term income, but the prudent entry is to wait for a close back above the 20-day or at least a successful test of the $19.70–$20.00 zone.

• Persistent consumer inflation and value-seeking behavior continue to pressure retail volumes; management does not expect a near-term improvement in consumer spending.
• Favorable pork input costs are a tailwind to margins, while logistics, fuel, and heat-related turkey feed conversion costs remain elevated.
• Portfolio-shaping divestitures, including Ceratti in Brazil and low-margin turkey/private-label snack-nut lines, are reducing reported revenue but should improve mix and margins over time.
• International operations face drags from an Indonesia minority-investment impairment and legal-entity transition issues that disrupted SPAM export recognition.
• A high dividend yield near 4.8% makes the stock more reliant on dividend safety and interest-rate conditions for valuation support.

• Q4 FY26 results and initial FY27 guidance in late November/early December 2026, which will be the first official look under incoming CEO John Ghingo.
• Continued adjusted operating margin expansion and supply-chain optimization; management raised FY26 adjusted EPS guidance to $1.45–$1.51.
• Foodservice growth — 12th consecutive quarter of organic growth — could accelerate and offset retail weakness.
• Completion of announced divestitures removes low-margin revenue and sets up easier year-over-year comparisons in FY27.

• Top-line stagnation becomes structural: retail volumes stay weak, private-label competition intensifies, and portfolio exits leave a smaller revenue base.
• Consumer pressure forces promotional spending that gives back the adjusted margin gains.
• Further one-time charges or impairments, especially in International, keep hitting GAAP results and shake confidence.
• CEO transition adds execution risk just as the company tries to finish its portfolio reshaping and re-accelerate growth.
• A 4.8% dividend yield is attractive only if earnings and free cash flow support it; any dividend caution would likely hit the stock hard.

Hormel is not a broken company — adjusted margins are improving, FY26 guidance was raised, the balance sheet is solid, and free cash flow is healthy. But it is also not a growth story: revenue is shrinking in the latest quarter and the consumer environment is weak. At $21.275, the stock offers a reasonable yield and a cheap forward multiple for patient income investors, but there is no compelling reason to chase it until top-line stabilization or a technical base appears. This reads as a hold/accumulate zone rather than a high-conviction buy.

I applied a 15.5x forward P/E multiple to next-FY consensus EPS of about $1.50, a deliberate discount to HRL's 5-year average P/E of 24.25x to reflect the flat-to-declining revenue outlook, partly offset by margin recovery, strong free cash flow, and the 4.8% dividend yield. That yields $23.25, modestly above the current price but below the analyst consensus target.